Jacopo Andreose, Angelini Pharma CEO

Italy's An­geli­ni Phar­ma teams up with JCR on blood-brain bar­ri­er deal

An­geli­ni Phar­ma plans to pay Japan­ese phar­ma JCR Phar­ma­ceu­ti­cals more than $500 mil­lion as part of a re­search col­lab­o­ra­tion that fo­cus­es on the blood-brain bar­ri­er.

The CNS-fo­cused phar­ma com­pa­ny, part of the Ital­ian con­glom­er­ate An­geli­ni In­dus­tries, put out word Thurs­day about the new de­vel­op­ment and com­mer­cial­iza­tion agree­ment, which aims to de­vel­op new treat­ments for epilep­sy.

As part of the de­vel­op­ment and com­mer­cial­iza­tion agree­ment, An­geli­ni will re­im­burse JCR for re­search ex­pens­es and pay an undis­closed up­front pay­ment — along with $505.5 mil­lion in mile­stones, plus roy­al­ties.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.